Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013)
Relmada Therapeutics (RLMD) posted quarterly Finished Goods of $4734.0 for Q4 2013, up 49.38% quarter-over-quarter from $3169.0 in Q3 2013.
Powered by 
Analysis
Relmada Therapeutics (RLMD) Finished Goods (2012 - 2013) Analysis & Trends
Relmada Therapeutics (RLMD) has reported Finished Goods for 2 consecutive years, with $4734.0 the latest figure, recorded in Q4 2013.
- In Q4 2013, Finished Goods changed N/A year-over-year to $4734.0; the TTM figure through Nov 2013 stood at $4734.0 (changed N/A YoY), while the FY2013 annual figure was $3169.0, down 50.52% from the prior year.
- Finished Goods rose to $4734.0 in Q4 2013 per RLMD's latest filing, from $3169.0 in the prior quarter.
- Across five years, Finished Goods topped out at $6405.0 in Q3 2012 and bottomed at $2369.0 in Q2 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Relmada Therapeutics | 498.39 Mn | 498.39 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Nov 30, 2013 | 4,734.00 |
| Aug 31, 2013 | 3,169.00 |
| May 31, 2013 | 2,369.00 |
| Feb 28, 2013 | 2,690.00 |
| Aug 31, 2012 | 6,405.00 |